Cargando…

Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis

Bone marrow stem cell (BMSC) transplantation during coronary artery bypass graft (CABG) is an innovative treatment for ischemic heart disease (IHD). We conduct a meta-analysis to examine whether patients with IHD presenting heart failure with reduced ejection fraction (HFrEF) can be beneficent from...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yinhao, Yang, Ziying, Shao, Lianbo, Shen, Han, Teng, Xiaomei, Chen, Yihuan, Ding, Yinglong, Fan, Jiaming, Yu, You, Shen, Zhenya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932762/
https://www.ncbi.nlm.nih.gov/pubmed/36786355
http://dx.doi.org/10.1177/09636897231152381
_version_ 1784889527005872128
author Jiang, Yinhao
Yang, Ziying
Shao, Lianbo
Shen, Han
Teng, Xiaomei
Chen, Yihuan
Ding, Yinglong
Fan, Jiaming
Yu, You
Shen, Zhenya
author_facet Jiang, Yinhao
Yang, Ziying
Shao, Lianbo
Shen, Han
Teng, Xiaomei
Chen, Yihuan
Ding, Yinglong
Fan, Jiaming
Yu, You
Shen, Zhenya
author_sort Jiang, Yinhao
collection PubMed
description Bone marrow stem cell (BMSC) transplantation during coronary artery bypass graft (CABG) is an innovative treatment for ischemic heart disease (IHD). We conduct a meta-analysis to examine whether patients with IHD presenting heart failure with reduced ejection fraction (HFrEF) can be beneficent from CABG with additional BMSC transplantation. Electronic searches were performed on PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov from their inception to July 2021. The efficacy was based on left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-diastolic volume (LVEDV), left ventricular end-diastolic volume index (LVEDVi), left ventricular end-systolic volume index (LVESVi), and 6-min walk test (6MWT) change after treatment. Eight randomized-controlled trials (RCTs) were included in this meta-analysis, with a total of 350 patients. Results showed BMSC transplantation significantly improved the LVEF [mean difference (MD) = 6.23%, 95% confidence interval (CI): 3.22%–9.24%, P < 0.0001], LVEDVi (MD = −20.15 ml/m(2), 95% CI: −30.49 to −9.82 ml/m(2), P < 0.00001), and LVESVi (MD = −17.69 ml/m(2), 95% CI: −25.24 to −10.14 ml/m(2), P < 0.00001). There was no statistically significant difference in the improvement of LVEDD, LVEDV, and 6MWT between the cell transplantation group and control groups. Subgroup analysis revealed that the intervention for control group could affect the efficacy of BMSC transplantation. Sensitivity analysis found the conclusion of LVEDD, LVEDV, and 6MWT changes was not stable. Therefore, among patients with IHD presenting HFrEF, BMSC transplantation during CABG is promising to be beneficial for postoperative left ventricular (LV) function improvement. However, according to the unstable results of the sensitivity analysis, it cannot be concluded whether the extra step has a positive effect on left ventricular remodeling and exercise capacity. RCTs with larger cohorts and more strict protocols are needed to validate these conclusions.
format Online
Article
Text
id pubmed-9932762
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-99327622023-02-17 Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis Jiang, Yinhao Yang, Ziying Shao, Lianbo Shen, Han Teng, Xiaomei Chen, Yihuan Ding, Yinglong Fan, Jiaming Yu, You Shen, Zhenya Cell Transplant Original Article Bone marrow stem cell (BMSC) transplantation during coronary artery bypass graft (CABG) is an innovative treatment for ischemic heart disease (IHD). We conduct a meta-analysis to examine whether patients with IHD presenting heart failure with reduced ejection fraction (HFrEF) can be beneficent from CABG with additional BMSC transplantation. Electronic searches were performed on PubMed, EMBASE, Cochrane Library, and ClinicalTrials.gov from their inception to July 2021. The efficacy was based on left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-diastolic volume (LVEDV), left ventricular end-diastolic volume index (LVEDVi), left ventricular end-systolic volume index (LVESVi), and 6-min walk test (6MWT) change after treatment. Eight randomized-controlled trials (RCTs) were included in this meta-analysis, with a total of 350 patients. Results showed BMSC transplantation significantly improved the LVEF [mean difference (MD) = 6.23%, 95% confidence interval (CI): 3.22%–9.24%, P < 0.0001], LVEDVi (MD = −20.15 ml/m(2), 95% CI: −30.49 to −9.82 ml/m(2), P < 0.00001), and LVESVi (MD = −17.69 ml/m(2), 95% CI: −25.24 to −10.14 ml/m(2), P < 0.00001). There was no statistically significant difference in the improvement of LVEDD, LVEDV, and 6MWT between the cell transplantation group and control groups. Subgroup analysis revealed that the intervention for control group could affect the efficacy of BMSC transplantation. Sensitivity analysis found the conclusion of LVEDD, LVEDV, and 6MWT changes was not stable. Therefore, among patients with IHD presenting HFrEF, BMSC transplantation during CABG is promising to be beneficial for postoperative left ventricular (LV) function improvement. However, according to the unstable results of the sensitivity analysis, it cannot be concluded whether the extra step has a positive effect on left ventricular remodeling and exercise capacity. RCTs with larger cohorts and more strict protocols are needed to validate these conclusions. SAGE Publications 2023-02-14 /pmc/articles/PMC9932762/ /pubmed/36786355 http://dx.doi.org/10.1177/09636897231152381 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Article
Jiang, Yinhao
Yang, Ziying
Shao, Lianbo
Shen, Han
Teng, Xiaomei
Chen, Yihuan
Ding, Yinglong
Fan, Jiaming
Yu, You
Shen, Zhenya
Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis
title Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis
title_full Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis
title_fullStr Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis
title_full_unstemmed Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis
title_short Clinical Outcomes by Consolidation of Bone Marrow Stem Cell Therapy and Coronary Artery Bypass Graft in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-analysis
title_sort clinical outcomes by consolidation of bone marrow stem cell therapy and coronary artery bypass graft in patients with heart failure with reduced ejection fraction: a meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932762/
https://www.ncbi.nlm.nih.gov/pubmed/36786355
http://dx.doi.org/10.1177/09636897231152381
work_keys_str_mv AT jiangyinhao clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis
AT yangziying clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis
AT shaolianbo clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis
AT shenhan clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis
AT tengxiaomei clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis
AT chenyihuan clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis
AT dingyinglong clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis
AT fanjiaming clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis
AT yuyou clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis
AT shenzhenya clinicaloutcomesbyconsolidationofbonemarrowstemcelltherapyandcoronaryarterybypassgraftinpatientswithheartfailurewithreducedejectionfractionametaanalysis